Laverock Therapeutics

Laverock Therapeutics, founded in 2021 and led by CEO David Venables, is developing a gene silencing platform for creating programmable advanced human therapeutic applications. GEiGS utilizes universal gene editing tools to minimally edit non-coding genes and direct their silencing activity (RNAi) to new target genes. It stands apart from other gene silencing methods through its core attributes of stability, adjustability, and programmability, ensuring cell type or condition-specific activity.Laverock is built around the core gene editing-induced gene silencing platform, marking a significant evolution in RNAi technology. We fundamentally believe it unlocks the development of next-generation therapies through its unique and differentiated properties. We are actively advancing a range of GEiGS-supported ex vivo cell therapies as well as in vivo treatment approaches.